Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9WRUG)

• Drug Name: BMS-344577 Drug Info
• Synonyms: BMS-344577; UNII-U259PQB19A; U259PQB19A; CHEMBL570867; 288079-93-6; BDBM35316; BDBM50328724; 2,5-Pyridinedicarboxamide, N5-((((3S)-hexahydro-2-oxo-1-(2-oxo-2-(1-pyrrolidinyl)ethyl)-1H-azepin-3-yl)imino)((2-methyl-5-benzofuranyl)amino)methyl)-N2,N2-dimethyl-; 2,5-Pyridinedicarboxamide, N5-((((3S)-hexahydro-2-oxo-1-(2-oxo-2-(1-pyrrolidinyl)ethyl)-1H-azepin-3-yl)amino)((2-methyl-5-benzofuranyl)amino)methylene)-N2,N2-dimethyl-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 44473100
  CAS Number: CAS 288079-93-6
  TTD Drug ID: DM9WRUG

Molecule-Related Drug Atlas

Drug(s) Targeting Tissue-type plasminogen activator (PLAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aminocaproic Acid	DMFGND4	Bleeding disorder	GA20-GA21	Approved	[2]
2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	DM3UMYD	Discovery agent	N.A.	Investigative	[3]
1-guanidino-N-phenyl-7-isoquinolinesulphonamide	DMTF1HL	Discovery agent	N.A.	Investigative	[4]
N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine	DMNO46U	Discovery agent	N.A.	Investigative	[5]
5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID	DMPFX0S	Discovery agent	N.A.	Investigative	[6]
N-(4-Phenyl-pyridin-2-yl)-guanidine	DMYD4PC	Discovery agent	N.A.	Investigative	[7]
N-(7-Benzyloxy-isoquinolin-1-yl)-guanidine	DMPMBC2	Discovery agent	N.A.	Investigative	[5]
N-(5-Benzyloxy-isoquinolin-1-yl)-guanidine	DMGAITY	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Coagulation factor Xa (F10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apixaban	DM89JLN	Thrombosis	DB61-GB90	Approved	[8]
Rivaroxaban	DMQMBZ1	Deep vein thrombosis	BD71	Approved	[9]
DU-176b	DMCIJBH	Atrial fibrillation	BC81.3	Approved	[10]
Emicizumab	DM0AQ83	Factor VIII deficiency	3B10	Approved	[11]
BETRIXABAN	DM2C4RF	Venous thromboembolism	BD72	Approved	[12]
Lmw heparin	DMJPD06	Coagulation defect	3B10.0	Approved	[13]
Nadroparin calcium	DMBNKST	Coagulation defect	3B10.0	Approved	[14]
Fondaparinux sodium	DMWS3FH	Deep vein thrombosis	BD71	Approved	[15]
Danaparoid	DM6CLBN	Deep venous clot	BD71	Approved	[16]
Coagulation Factor IX	DM8HBJI	Haemophilia B	3B11.0	Approved	[17]

Drug(s) Targeting Coagulation factor IIa (F2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Argatroban	DMFI46A	Thrombosis	DB61-GB90	Approved	[18]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[19]
Bivalirudin	DMECRX1	Thrombocytopenia	3B64	Approved	[20]
Ximelegatran	DMU8ANS	Myocardial infarction	BA41-BA43	Approved	[21]
Dabigatran	DMDI6R4	Stroke	8B20	Approved	[22]
Desirudin Recombinant	DM2BTFN	Coagulation defect	3B10.0	Approved	[23]
Human prothrombin complex concentrate	DMPHVQ1	Bleeding disorder	GA20-GA21	Approved	[24]
Lepirudin	DM1I3D5	Thrombocytopenia	3B64	Approved	[25]
Anisindione	DM2C48U	Coagulation defect	3B10.0	Approved	[26]
ATryn antithrombin	DM79Y2T	Multiple sclerosis	8A40	Approved	[27]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor IIa (F2)	TT6L509	THRB_HUMAN	Inhibitor	[1]
Coagulation factor Xa (F10)	TTCIHJA	FA10_HUMAN	Inhibitor	[1]
Tissue-type plasminogen activator (PLAT)	TTXAGYU	TPA_HUMAN	Inhibitor	[1]

References

• [1] Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9.
• [2] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [3] Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
• [4] Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51.
• [5] Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
• [6] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [7] Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines. Bioorg Med Chem Lett. 2002 Jan 21;12(2):181-4.
• [8] Pfizer. Product Development Pipeline. March 31 2009.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
• [11] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [12] Company report (Portola)
• [13] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [14] Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
• [15] Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
• [16] Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
• [17] Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.
• [18] Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
• [19] New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
• [20] New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
• [21] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [22] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
• [25] Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
• [26] Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
• [27] Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.